抗新生血管生成药ramucirumab的药理作用及临床评价  

Pharmacology and clinical evaluation of the anti-angiogenesis agent ramucirumab

作　　者：马英 汪汀 马轶鸣 林碧蓉 

机构地区：[1]上海中信国健药业股份有限公司,上海201203

出　　处：《中国新药杂志》2014年第20期2339-2343,共5页Chinese Journal of New Drugs

摘　　要：Ramucirumab是礼来公司研发的重组全人IgG1单克隆抗体。本品可以特异性结合人血管内皮生长因子受体2(VEGFR2)的胞外结构域,阻止VEGFR2与血管内皮生长因子A,C,D(VEGF-A,VEGF-C,VEGF-D)的相互作用,从而抑制VEGF激活VEGFR2以及下游信号传导途径。2014年4月,FDA批准了ramucirumab单药用于治疗先前氟尿嘧啶或铂制剂化疗后发生疾病进展的晚期或转移性胃癌或胃-食管结合部腺癌患者。本文对ramucirumab的药理作用、药动学、临床有效性及安全性等进行了综述。Ramucirumab is a recombinant human immunoglobulin G1（ IgG1） monoclonal antibody developed by Eli Lilly. Ramucirumab can specifically bind to human vascular endothelial growth factor receptor 2（ VEGFR2） and effectively prevent the interaction between VEGFR2 and its ligands（ including VEGF-A,VEGF-C and VEGF-D）. The blockade of VEGFR2 can inhibit the activation of VEGFR2 and downstream signaling transduction.Its indication for the treatment of patients with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine-or platinum-containing chemotherapy has been approved by FDA on April 2014. This article summarized the pharmacology,pharmacokinetics,clinical efficacy and safety profiles of ramucirumab.

关 键 词：ramucirumab 血管内皮生长因子受体2 新血管生成 胃癌 胃-食管结合部腺癌 

分 类 号：R979.1[医药卫生—药品]